Mathias Svahn

Mathias Svahn

Company: NextCell Pharma

Job title: Chief Executive Officer

Seminars:

BREAKOUT DISCUSSION GROUPS 12:00 pm

• What are the limitations of large scale manufacturing of devices and will the bespoke nature of each company’s device hinder commercialization? • What is the feasibility of hybrid differentiation systems and moving from 2D to 3D mid differentiation on a large scale? • What are the GMP facility requirements to manufacture beta cells at…Read more

day: Day Two

PANEL DISCUSSION: Moving Towards Commercialization – Forward Thinking Strategies 11:00 am

• Determining suitable risk analyses for supply chain, logistics and durability of suppliers • Debating diversifying source providers to avoid supply deficits • How do you ensure providers can meet the scale you need? • Highlighting the importance of communicating with the FDA and regulatory bodies to ensure a smooth route to commercialization • Assessing…Read more

day: Day Two

CASE STUDY: The Development of Allogeneic Mesenchymal Stem Cell Therapies for Type 1 Diabetes 9:20 am

• Preserve endogenous insulin production in adult patients diagnosed with type I diabetes by immunomodulatory allogeneic mesenchymal stromal cells • Redundant source of primary hMSC for scalable manufacturing • Selection algorithm developed to select optimal cells based on multiple functional assays and mechanisms of action • Drug product currently in two clinical trialRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.